Improved heart function follows enhanced inflammatory cell recruitment and angiogenesis in 11 beta HSD1-deficient mice post-MI

Citation for published version:

Digital Object Identifier (DOI):
10.1093/cvr/cvq149

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Cardiovascular Research

Publisher Rights Statement:
© The Author 2010. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits noncommercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Improved heart function follows enhanced inflammatory cell recruitment and angiogenesis in 11βHSD1-deficient mice post-MI

Sara J. McSweeney†, Patrick W.F. Hadoke, Agnieszka M. Kozak, Gary R. Small‡, Hiba Khaled, Brian R. Walker, and Gillian A. Gray*

Centre for Cardiovascular Science, Queen’s Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ Scotland, UK

Received 22 January 2010; revised 3 May 2010; accepted 17 May 2010; online publish-ahead-of-print 21 May 2010

Time for primary review: 17 days

Aims

Mice unable to locally regenerate corticosterone due to deficiency of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) have enhanced angiogenesis during acute myocardial infarct healing. The present study investigates the hypotheses that in these mice (i) inflammation and angiogenic signalling are promoted and (ii) longer-term remodelling and function are improved.

Methods and results

Myocardial infarction (MI) was induced by coronary artery ligation in 11βHSD1−/− and wild-type (C57BL/6) mice. Studies were terminated 2, 4, 7, and 28 days post-surgery. Increased vessel density (CD31 immunoreactivity) on the infarct border was confirmed 7 days after MI in 11βHSD1−/− hearts (P<0.05) and was accompanied by improved ejection fraction (ultrasound) compared with C57BL/6. During wound healing, recruitment of neutrophils (at 2 days after MI) and macrophages (from 4 days after MI) and expression of monocyte-chemoattractant protein-1 was increased in 11βHSD1−/− compared with C57BL/6 hearts (P<0.05). Recruitment of alternatively activated YM1-positive macrophages was particularly enhanced in the period preceding increased vessel density and was accompanied by increased expression of pro-angiogenic IL-8. By 28 days post-MI, when the infarct scar had matured, higher vessel density was maintained in 11βHSD1−/− hearts and vessels were smooth-muscle coated. Infarct scars were thicker (P<0.001) in 11βHSD1−/− compared with C57BL/6 hearts and ejection fraction was higher (P<0.05).

Conclusion

Increased vessel density in healing infarcts of mice deficient in 11βHSD1 follows recruitment of pro-reparative macrophages and increased pro-angiogenic signalling. Mature infarcts show less thinning and cardiac function is improved relative to wild-type mice, suggesting that 11βHSD1 may be a novel therapeutic target after MI.

Keywords

Angiogenesis • Inflammation • Alternatively activated macrophages • YM1 • IL-8

1. Introduction

Infarct expansion is an important determinant of long-term outcome following myocardial infarction (MI). Therapeutic strategies aimed at limiting infarct size, such as reperfusion, have led to reduction of acute mortality post-MI. Despite this intervention, patients still develop heart failure.1 Enhancing blood supply to the infarct border through stimulation of angiogenesis, e.g. by injection of putative cell progenitors or pro-angiogenic factors into the myocardium, reduces infarct expansion and remodelling, and improves heart function in experimental MI.1–3 However, translation of this strategy to the clinic has had limited success to date.4,5 An alternative approach is to manipulate endogenous mechanisms involved in infarct healing so that the associated angiogenic response is promoted.

Activation of corticosteroid receptors is regulated in target tissues by pre-receptor metabolism of glucocorticoids by the isozymes of 11β-hydroxysteroid dehydrogenase (11βHSD).6 Following secretion of active glucocorticoids (principally cortisol in humans and...
corticosterone in rodents) from the adrenal cortex under the control of ACTH, these steroids are inactivated by 11βHSD2 (to cortisone and 11-dehydrocorticosterone, respectively) in the kidney and a few other tissues. These inert metabolites are then regenerated into active glucocorticoid by 11βHSD1, which is expressed primarily in glucocorticoid target tissues and has been implicated in the regulation of cognitive, metabolic, and cardiovascular function. Importantly, 11βHSDs influence the intracellular concentrations of active glucocorticoids independently of any change in circulating plasma glucocorticoids levels; changes in 11βHSD activity do alter metabolic clearance rate of glucocorticoids, but the circulating level of cortisol (or corticosterone) is maintained by compensatory changes in ACTH and adrenal secretion. In the cardiovascular system, 11βHSD1 is expressed in the heart and in the vascular wall. In a previous study, we showed that mice deficient in 11βHSD1 have enhanced capacity for angiogenesis, and that vessel density is increased during infarct healing after MI. However, the mechanism of increased neo-vascularization in the hearts of 11βHSD1−/− mice is unknown, as are the functional consequences for the heart. Inflammatory cells, particularly monocyte/macrophages, are an important source of pro-angiogenic cytokines, such as vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8). Depletion of monocytes/macrophages after experimental MI results in impaired angiogenesis on the infarct border. In contrast, enhancement of monocyte recruitment by overexpression of monocyte chemoattractant protein-1 (MCP-1), or direct injection of activated macrophages into the heart, increases vessel density on the infarct border and improves heart function.

Glucocorticoids are released into the systemic circulation acutely after MI and appear to be initially cardioprotective, as blockade of the glucocorticoid receptor (GR) increases infarct size. However, experimental and clinical studies have shown that prolonged exposure to high systemic levels of glucocorticoid, achieved by administration of synthetic glucocorticoids, is detrimental following MI. Consistent with the ability of glucocorticoid to suppress inflammatory processes essential for infarct healing, deficiency of 11βHSD1 exacerbates inflammation in murine models of arthritis and sterile peritonitis, suggesting that locally regenerated glucocorticoid also suppresses inflammation.

The present study was designed to investigate the hypothesis that the lack of local glucocorticoid regeneration in 11βHSD1−/− mice results in modification of the inflammatory response after MI resulting in promotion of pro-angiogenic signalling in the healing myocardial infarct. We also aimed to investigate whether the vessels formed early after MI are retained after infarct healing is complete and importantly, whether there are beneficial consequences for cardiac remodelling and function in 11βHSD1−/− mice.

2. Methods

2.1 Animals

Ten- to 12-week-old male 11βHSD1 knock out (11βHSD1−/−) congenic with C57BL/6 mice were bred from an in-house colony. Controls were commercial C57BL/6 mice (Harlan). The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health (NIH Publication No 82-23 revised 1996) and was approved by the University of Edinburgh ethics committee.

2.2 Coronary artery ligation

Mice (n = 128) were anaesthetized (1 mg/kg medetomidine, 75 mg/kg ketamine, and 600 μg/kg atropine) and received buprenorphine (0.05 mg/kg) for analgesia. The trachea was intubated for mechanical ventilation (120 strokes/min, 200 μL stroke volume, Hugo Sachs Elektronik Minivent). The left thorax was opened at the fourth intercostal space and the left main descending coronary artery was ligated with a 6.0 prolene suture. Sham animals did not have the ligature tied. Following surgery mice received the reversal agent atipamezole (5 mg/kg) and 1.5 mL sterile saline intraperitoneally, and oxygen-enriched air until fully recovered.

2.3 Corticosterone radioimmunoassay

Plasma corticosterone levels 24 h and every 7 days after surgery at the diurnal nadir were measured by radioimmunoassay as described previously.

2.4 Ultrasound and tissue collection

At 2, 4, 7, or 28 days after surgery, heart function was assessed by ultrasound (Diason 10–22 MHz probe, Dynamic Imaging, Livingstone, UK). Left ventricular ejection fraction (%EF) was calculated as detailed in the Supplementary Methods. The observer was blinded for ultrasound measurements and all other analyses.

2.5 Infarct size measurement

Infarct size at 24 h after MI was measured by triphenyltetrazolium chloride (TTC, Sigma) staining as described previously.

2.6 Histology and immunohistochemistry

Haematoxylin and eosin, Picrosirius Red, and Masson’s Trichrome stains were used to identify neutrophils, collagen, and the infarct scar, respectively. Immunohistochemistry was used to identify endothelial cells (anti-CD31, BD Pharmingen), proliferating cells (anti-BrdU, Sigma), alternatively activated macrophages (anti-CD31, BD Pharmingen), and activated myofibroblasts [anti-α smooth muscle actin (SMA, Sigma), Biotinylated secondary antibodies (rabbit anti-rat, goat anti-mouse, and goat anti-rabbit, 1:200, Vector) were subsequently added prior toextravidin peroxidase (Sigma). Detection of peroxidase activity was with the 3,3-diaminobenzidine kit (Vector). Sections were counterstained with haematoxylin, dehydrated, and mounted in DPX resin (Fluka). See Supplementary Methods for further details.

For quantification, sections were tiled at ×25 or ×100 magnification (Image Pro6.2, Stereologer Analyser 6 MediaCybernetics). Neutrophils (identified morphologically) and counted in 10 randomly assigned 40 μm² areas of left ventricle (LV); CD31 and αSMA positive vessels (less than 200 μm in diameter) were counted in 10 randomly assigned 400 μm² areas of LV, and an average per LV calculated. BrdU positive cells were counted per mm². Macrophage (Mac 2 and YM1) staining was calculated based on percentage staining of the infarct border. The area of collagen deposition (Picrosirius Red) and scar area (Mason’s Trichrome) were quantified as a percentage of the total LV. Scar thickness was calculated from the thickness of three points on the scar and averaged. Epicardial infarct length was calculated as epicardial infarct length/epicardial length × 100.
2.7 RNA isolation and quantitative real-time reverse-transcription polymerase chain reaction

One microgram RNA extracted from the frozen half heart using Trizol (Invitrogen, Paisley, UK) was reverse transcribed to cDNA (Applied Biosystems high capacity cDNA reverse transcription kit). Taqman® gene expression assays were used to detect interleukin 6 (IL-6 Mm99999064_m1), monocyte chemotactic protein 1 (MCP-1 Mm00441242_m1), and KC (mouse homologue of interleukin 8 which will be referred to as IL-8, Mm00433859_m1). mRNA expression levels were normalized for GAPDH expression and presented as fold increases over sham control analysed in parallel.

2.8 Statistical analysis

All values are expressed as mean ± SEM. Comparisons of day 2–7 data are by two-way ANOVA with Bonferroni post hoc tests, with the exception of qRT–PCR data which are by Kruskal–Wallis testing. Two-tailed unpaired Student’s t-tests were used to compare infarct size and 28 day data. P-values < 0.05 denote statistical significance.

3. Results

3.1 Survival, infarct size, and plasma corticosterone after MI

Survival rate was 76% (63/83 total) in C57BL/6 and 78% (35/45 total) in 11βHSD1−/− mice, and in both groups, death was due to acute heart failure or rupture during early infarct healing. TTC staining showed that the extent of LV damage 24 h after MI was comparable in C57BL6 (35.1 ± 1.0% of LV, n = 6) and 11βHSD1−/− (37.8 ± 2.4%; n = 6) mice. At this time, the plasma corticosterone concentration was 10-fold higher than basal levels. Plasma corticosterone declined by day 7 to approximately 75 nmol/L (Supplementary material online, Figure S1) in both C57BL/6 and 11βHSD1−/− mice.

3.2 Inflammatory cell recruitment during infarct healing

At 2 days after MI, there was significant neutrophil recruitment to the LV relative to sham operation (P < 0.01, Figure 1). In 11βHSD1−/− mice, the number of neutrophils in the LV at this time was significantly enhanced compared with C57BL/6 (P < 0.01). Thereafter, neutrophil content decreased to similar levels as the sham-operated controls in both groups (Figure 1). Early expression of the neutrophil chemo-attractants IL-6 and IL-8 did not increase significantly in 11βHSD1−/− compared with C57BL/6 mice (day 2 IL-6 expression 1.14 ± 0.01 relative to sham in C57BL/6 and 1.22 ± 0.02 relative to sham in 11βHSD1−/−; day 2 IL-8 expression 1.14 ± 0.01 relative to sham in C57BL/6 and 1.17 ± 0.02 relative to sham in 11βHSD1−/−, n = 6 per group).

Mac 2 immunoreactive macrophages were identified predominantly in the infarct and border zone, becoming evident from 2 days after MI (Figure 2D and E). The extent of Mac 2 immunoreactivity was further increased at 4 and 7 days post-MI relative to sham operation (P < 0.001, Figure 2A and E). In hearts from 11βHSD1−/− mice, macrophage accumulation tended to be increased relative to controls and this was significant by 7 days after MI (P < 0.01, Figure 2A). Flow cytometric analysis of LV homogenates also demonstrated increased content of CD11b+ve monocyte/macrophages in 11βHSD1−/− hearts at this time (data not shown). Expression of the macrophage chemoattractant MCP-1 mRNA was also greater in the LV of 11βHSD1−/− compared with control mice 7 days after MI (P < 0.01, Figure 2B). Specific immunostaining for the subset of pro-angiogenic and reparative ‘alternatively-activated’ macrophages, identified by YM1, revealed increased accumulation at 4 and 7 days post-MI relative to sham-operated mice, in which staining was negligible (Figure 2C and F). In 11βHSD1−/− mice, accumulation of YM1-positive macrophages was significantly greater than in C57BL6 controls (P < 0.05) by 4 days after MI (Figure 2C). Detection of activated myofibroblasts using α-smooth muscle actin (αSMA) showed significant accumulation of immunopositive cells from 4 days after MI (Supplementary material online, Figure S2), consistent with scar maturation. However, there was no significant influence of genotype on αSMA immunoreactivity at either time point.

3.3 Post-infarct neovascularization and pro-angiogenic signalling

The density of small (<200 μm in diameter) CD31-positive blood vessels increased after MI, particularly on the infarct border (Figure 3A and C). Consistent with increased vessel formation, cell proliferation, identified by BrdU incorporation, was also increased at the same site (Figure 3B and C). By 7 days after MI, both vessel density (P < 0.05, Figure 3A) and cell proliferation (P < 0.01, Figure 3B and C) were significantly higher in 11βHSD1−/− than in C57BL6 control hearts. This was accompanied by increased abundance of the pro-angiogenic signalling molecule IL-8 mRNA in the LV of 11βHSD1−/− hearts (P < 0.01, Figure 3D). Expression of
VEGF mRNA was not increased after MI in either C57BL/6 or 11βHSD1−/− hearts at this time (Figure 3D) or earlier during infarct healing (e.g. VEGF expression was 1.02 ± 0.09 and 1.00 ± 0.05 compared with sham in C57BL/6 at 2 and 4 days after MI; 1.02 ± 0.03 and 0.98 ± 0.02 compared with sham in 11βHSD1−/− hearts at 2 and 4 days after MI, n = 6 per group).

### 3.4 Cardiac function during early infarct healing

There were no differences in basal cardiac function between un-operated 11βHSD1−/− and C57BL/6 mice (Supplementary material online, Table S1). After sham operation, ejection fraction (EF) was consistently above 60% in both C57BL/6 and 11βHSD1−/− mice, and was not different between these two groups (see Supplementary material online, Table S1). After MI, EF was significantly reduced in all mice, compared with sham operation (e.g. at 7 days after surgery EF was 32 ± 4% in MI compared with 64 ± 5% in sham-operated C57BL/6 mice, P < 0.01). EF was similarly depressed in both C57BL/6 and 11βHSD1−/− at 2 and 4 days after MI (Figure 4). However, by 7 days after MI, EF was significantly improved in 11βHSD1−/− compared with control mice (P < 0.05, Figure 4).

### 3.5 Post-infarct healing characterization

Investigation of cardiac function at 28 days after MI, when infarct healing was largely complete, revealed that the improvement in function in 11βHSD1−/− mice apparent at 7 days after MI was
Dysfunction post-MI was not associated with chamber dilatation at this point, as LV end-diastolic area remained consistent throughout the post-operative period in all mice (data not shown).

In hearts collected 28 days after MI, the density of small CD31-positive vessels also remained higher in 11bHSD1\(^{-/-}\) relative to C57BL/6 hearts (\(P < 0.05\), Figure 5A). Furthermore, the number of \(\alpha\)SMA immunopositive vessels was also increased in 11bHSD1\(^{-/-}\) hearts (\(P < 0.001\), Figure 5B), suggesting that some of the new vessels had matured and become pericyte coated (Figure 5C). The extent of fibrosis and scar area, evaluated by Picrosirius Red and Masson’s Trichrome staining, were comparable between control and 11bHSD1\(^{-/-}\) mice 28 days post-MI (Figure 6A and B). However, 11bHSD1\(^{-/-}\) mice had significantly thicker infarcts than C57BL/6 mice (\(P < 0.001\), Figure 6C and E) and the scars had a tendency to be shorter (Figure 6D).

4. Discussion

We have previously shown that deficiency of 11bHSD1 is associated with increased vessel formation in experimental models of angiogenesis in vitro and in vivo, including in the healing myocardium of mice that have undergone MI.\(^{13}\) In the current study, we aimed to extend these observations by investigating whether modification of inflammation during infarct healing might provide a stimulus for increased vascularization in 11bHSD1\(^{-/-}\) mice. We additionally aimed to investigate whether these acute vascular changes translated into sustained functional improvement. The data demonstrate that increased neovascularization during infarct healing in 11bHSD1\(^{-/-}\) mice follows increased accumulation of neutrophils and of alternatively activated macrophages, and occurs in parallel with increased expression of the pro-angiogenic chemokine, IL-8. Furthermore, enhanced blood...
vessel density is retained at 28 days post-MI in 11βHSD1−/− mice, by which time vessels on the infarct border have matured, scar thinning is reduced, and cardiac function is improved.

Neovascularization on the infarct border typically begins during the reparative phase of healing. In the present study, the number of CD31-positive blood vessels in the LV increases during this period between 4 and 7 days after MI. Increased incorporation of BrdU into cells on the infarct border over the same period is consistent with the endothelial cell proliferation that is known to contribute to new blood vessel formation. In mice deficient in 11βHSD1, vessel density is higher during infarct healing, in agreement with our previous observations, and cellular proliferation is also significantly increased. Glucocorticoids are known to suppress endothelial cell proliferation. Promotion of angiogenesis in the hearts of 11βHSD1−/− mice is consistent with lifting of this suppression in mice unable to regenerate glucocorticoid, permitting enhanced proliferation. The primary stimulus for neovascularization after MI is from pro-angiogenic cytokines and chemokines released by neighbouring cells in the infarct. IL-8 is secreted by macrophages and endothelial cells in the healing infarcts, acts as a chemoattractant for bone marrow-derived endothelial progenitor cells, and can promote endothelial cell proliferation. In the present study, we find that expression of IL-8 is significantly increased in the LV of 11βHSD1−/− mice, suggesting that mechanisms other than direct regulation of cellular proliferation may contribute to increased neovascularization in the absence of 11βHSD1 activity.

Monocyte/macrophages have a key role in regulation of injury-associated angiogenesis. When macrophage accumulation in the infarct is prevented, following depletion by liposome-encapsulated clodronate, angiogenesis is abolished. Glucocorticoids downregulate inflammatory cytokines, upregulate anti-inflammatory cytokines, and modulate phagocytosis by macrophages. Macrophages express 11βHSD1 and its expression is upregulated after activation, which may serve to curtail the inflammatory response in the healing myocardial infarct. In support of this hypothesis, investigation of hearts from 11βHSD1−/− mice after MI reveals that accumulation of both neutrophils and macrophages is magnified in comparison to hearts from C57BL/6 mice. Infarct size is a key stimulus for inflammatory cell infiltration after MI, but deficiency of 11βHSD1 has no effect on ischaemia-associated damage to the myocardium. Systemic corticosterone, released from the adrenal gland in response to surgical stress and MI, is another potential modulator of myocardial inflammation. However, the 11βHSD1−/− mice have comparable basal systemic corticosterone and response to MI as the wild-type mice; this is consistent with control of circulating corticosterone by ACTH being independent of peripheral 11βHSD activity, and with previous reports of normal plasma corticosterone in 11βHSD1−/− mice on a C57BL/6 background. If anything, plasma corticosterone levels tended to be a little higher in 11βHSD1−/− mice after MI, which also occurs with 11βHSD1 deletion on a mixed genetic background and would be anticipated to oppose the beneficial effects on outcome from MI observed here. This emphasizes that local intracellular changes in glucocorticoid generation in the heart, or elsewhere, are more likely to be regulating the inflammatory response post-MI.

Neutrophils are attracted to the heart very soon after infarction and contribute to cell removal during the early inflammatory phase of infarct healing as well as releasing cytokines e.g. IL-4 that regulate the later reparative phase. Enhanced neutrophil accumulation in 11βHSD1 hearts may therefore impact on both of these phases of infarct repair. The mechanism of increased neutrophil accumulation in 11βHSD1−/− hearts is not clear. Recruitment is regulated by IL-6 and IL-8, but there is no difference in expression of these cytokines in 11βHSD1−/− compared with C57BL/6 hearts, at least at 2-day post-MI mice. This may indicate that early cytokine expression is not a mechanism for enhanced neutrophil recruitment in 11βHSD1−/− mice. However, we cannot rule out the possibility that acute differences in expression may have been masked by the changes in cytokine expression that are associated with acute surgical trauma, as previously described. Mice deficient in glucocorticoids following adrenalectomy have increased expression of the adhesion molecules that have a role in tethering neutrophils to the endothelium prior to translocation into inflamed tissue. Reduced availability of glucocorticoids in the 11βHSD1−/− mice may therefore provide a similar stimulus for enhanced retention of neutrophils post-MI. Once in the infarct, neutrophils undergo apoptosis and are removed by the phagocytic activity of macrophages. An alternative explanation for our findings is that neutrophils undergo less or

Figure 5 Blood vessel density and pericyte coverage 28 days after MI. (A) CD31 and (B) α-smooth muscle actin (αSMA smooth muscle cells) positive vessels <200 μm in diameter counted in sequential sections from the LV, expressed per 400 μm². (C) Representative sections showing typical double immuno-staining for CD31 (brown) and αSMA (blue) on the infarct border of C57BL/6 (C57BL/6) and 11βHSD1−/− (11βHSD1−/−) hearts. Filled arrows point to pericyte, smooth muscle coated vessels, open arrows point to pericyte poor, smooth muscle negative vessels. n = 10, C57BL/6; n = 9, 11βHSD1−/−. *P < 0.05, ***P < 0.001. Scale bar, 10 μm.
delayed apoptosis in 11bHSD1−/− mice. There is, however, no evidence for delayed neutrophil removal in 11bHSD1−/− compared with C57Bl/6 mice. Furthermore, this mechanism appears unlikely as glucocorticoids tend to inhibit neutrophil apoptosis and reduced local glucocorticoid availability would therefore be expected to enhance, rather than reduce neutrophil apoptosis.

Monocytes are attracted to the infarct by monocyte chemotactic protein-1 (MCP-1), also secreted by macrophages. In the present study, expression of MCP-1 mRNA is increased in 11bHSD1−/− hearts in parallel with increased macrophage accumulation. Nahrendorf et al. have suggested that alternatively activated, pro-angiogenic monocytes present during the reparative phase of healing play a vital role in infarct healing. Unlike classically activated macrophages that secrete pro-inflammatory mediators and display phagocytic behaviour, alternatively activated macrophages secrete anti-inflammatory and angiogenic cytokines such as TGFβ, IL-4, and IL-8 and can be identified by secretion of the chitinase-like molecule YM1. Data presented here shows for the first time that YM1-positive macrophages are indeed present in healing myocardial infarcts. Furthermore, immunostaining revealed the presence of a greater proportion of YM1-positive, alternatively activated macrophages in the infarct border of 11bHSD1−/− mice during the reparative phase of healing. These macrophages are the likely source of IL-8, expression of which is increased at the time of angiogenesis in the 11bHSD1−/− mice. Further studies are required to elucidate the mechanism for preferential assumption of the pro-reparative phenotype in 11bHSD1−/− mice and to investigate its importance in determining the increased vessel density in these mice.

It is clear from many studies that enhancement of angiogenesis on the infarct border post-MI improves heart function. In the present study, we show that cardiac function in 11bHSD1−/− mice is similar to that in C57BL/6 mice early after infarction, but by 7 days post-MI, at the time when increased vessel density is clear, ejection fraction is also enhanced. Increased vessel density early after infarction therefore appears to be of benefit, potentially by increasing blood supply to cardiomyocytes on the infarct border, but if this is to remain it is important that the early capillaries mature so that blood supply is maintained. As the scar heals, the early vessels are either pruned or they mature by gaining pericyte coverage. In hearts of 11bHSD1−/− mice, we show that increased vessel density is retained at 28 days post-MI, by which time many of the vessels have become smooth muscle coated. Correspondingly, ejection fraction also remained higher in 11bHSD1−/− compared with control mice at this time. By 28 days after MI, the infarcted myocardium was replaced by a collagen rich scar. Assessment of the scar structure revealed that although the overall scar area was similar, scars from 11bHSD1−/− mice were thicker and tended to be shorter than those from control mice. Failure to show a significant reduction in scar length is a limitation of the study, likely because of insufficient mice to account for the variability in this parameter. It is possible

Figure 6 Fibrosis and scar formation 28 days after MI. (A) Collagen deposition measured from Picrosirius Red stained sections and expressed as percent staining of the LV in C57BL6 (C57BL6, light columns) and 11bHSD1−/− (11HSD1−/−, dark columns) hearts. (B–E) Scar dimensions and infarct lengths were assessed from Masson’s Trichrome stained sections (B). (C) Scar area expressed as the percentage of the LV. (D) Scar thickness was averaged from three points taken across the scar. (E) Epicardial infarct length expressed as a percentage of the epicardial LV length. n = 10, C57BL6 MI; n = 9, 11bHSD1−/− MI for Picrosirius Red and Masson’s Trichrome staining. ***p < 0.001 (C57BL6 versus 11bHSD1−/−). Scale bar, 10 μm.
that enhancement of blood supply to the infarct border resulted in salvage of cardiomyocytes, as has previously been reported.50 Reducing infarct expansion and contributing to increased cardiac contractility. The chitinase-like activity of YM1, present to a greater extent in 11βHSD1−/− mice, can aid in matrix reorganization and wound healing,48,51 and this may also have contributed to the reduction in infarct thinning observed in these mice. Macrophages have an important role in scar formation by enhancing fibrosis.52 Macrophage secretion of transforming growth factor-β can activate myofibroblasts subsequently leading to collagen production.53,54 However, the data presented here indicate that despite greater macrophage accumulation in 11βHSD1−/− mice, myofibroblast activation and fibrosis were not increased relative to controls.

In summary, the present results support the hypothesis that inflammatory cell recruitment after MI is modified in mice deficient in 11βHSD1 and that this provides an enhanced stimulus for angiogenesis in the healing infarcts of these mice. Furthermore, increased vessel density is associated with reduction of infarct thinning and sustained functional improvement after MI. Glucocorticoids can activate both GR and mineralocorticoid receptor (MR). Blockade of MR soon after MI resulted in improvement in cardiac function in the EPHEMUS clinical trial34 and in an experimental model of MI.35 It may therefore be prevention of MR activation by locally generated corticosterone that accounts for the present observations in 11βHSD1−/− mice, and this requires confirmation in further studies. While the MR antagonist Eplerenone is currently being used clinically post-MI, it can lead to hyperkalaemia.54 Inhibitors of 11βHSD1 are in phase II trials for treatment of diabetes and other data suggest that they will prove beneficial in obesity and atherosclerosis.55 The present data suggest that they may also provide an alternative approach for regulation of corticosteroid activity after MI.

Supplementary material

Supplementary material is available at Cardiovascular Research online.

Acknowledgements

We thank Jonathan R. Seckl and John J. Mullins for the provision of the 11βHSD1−/− mice and Hector Scott and Susan Harvey for their assistance with histology and immunohistochemistry. We acknowledge the support of the British Heart Foundation Centre of Research Excellence.

Conflicts of interest: none declared.

Funding

This work was supported by The Hypertension Trust.

References


11β-HSD1 and myocardial infarct healing

11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) plays a key role in regulating glucocorticoid (GC) levels and is involved in various physiological processes, including inflammatory responses and cardiovascular disease. This enzyme converts inactive 11-dehydrocorticosteroids to active GCs, which plays a crucial role in cardiovascular function and remodeling following myocardial infarction (MI).

Recent studies have shown that inhibition of 11β-HSD1 ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. However, the full spectrum of macrophage activation, including the role of 11β-HSD1 in cardiovascular diseases, remains to be fully understood.


Other research has focused on the role of 11β-HSD1 in monocyte recruitment and neutrophil mobilization, highlighting its importance in various physiological processes.

In summary, 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. Further research is needed to fully understand the role of 11β-HSD1 in cardiovascular diseases and to develop targeted therapies for these conditions.